Version June 2024
| Trial* (author, yr) | n | Age median (range), years | Induction | Consolidation | Maintenance | CNS-P | CR, percent | MRD, mos | MS, mos | DFS percent, yrs |
| GMALL 01 (Hoelzer 1988) | 368 | 25 (15-65) | V, P, D, A, C, Ara- C, MP | V, Dex, Dox, C, Ara-C, TG | MP, MTX | IT MTX, XRT | 74 | 24 | 28 | 35 (10) |
| SWOG L10M (Hussein 1989) | 168 | 28 (15-85) | V, P, Dox, C | Ara-C, MTX, TG, V, P, A, C | V, P, Dox, MP, MTX, Dac, C, BCNU | IT MTX | 68 | 23 | 18 | NR |
| MDACC (Kantarjian 1990) | 105 | 30 | V, Dox, Dex ± C | MTX, A, Dox, Ara-C, V, P, ± allo HCT | MP, MTX, D, P | 84 | 22 | 19 | 34 (5) | |
| UCSF (Linker 1991) | 109 | 25 (16-49) | V, P, D, A | V, P, D, A, Ara-C, VM- 26, MTX | MP, MTX | IT MTX, XRT | 88 | NR | NR | 35 (5) |
| ECOG 3486 (Cassileth 1992) | 247 | a) 35 | a) V, P, D | HD Ara-C; | - | - | a) 73 | NR | a) 9 | a) 17 (2) |
| b) 32 | b) V, P, D, Ara-C, TG | MTX, A, C, Dox, V, P | - | - | b) 58 | NR | b) 11 | b) 35 (2) | ||
| LALA87 (Fiere 1993) | 511 | 33 | C, V, P, D or C, V, P, Z | Ara-C, A, with D or Z, allo-HCT or auto-HCT | V, P, MP, MTX, Dox, C, BCNU | IT MTX | 76 | 17 | 18 | chemo, 32 allo-HCT, 43 auto-HCT, 39 |
| CALGB 8811 (Larson 1995) | 197 | 32 (16-80) | V, P, D, A, C | C, Ara-C, MP, V, A, Dox, Dex, TG | V, P, MP, MTX | IT MTX, XRT | 85 | 29 | 36 | 46 (3) |
| CALGB 9111 (Larson, 1998) | 198 | 35 (16-83) | V, P, D, A, C | C, Ara-C, MP, V, A, Dox, Dex, TG | V, P, MP, MTX | IT MTX, XRT | 85 | NR | 23 | 40 (3) |
| GIMEMA 0288 (Annino 2002) | 778 | 28 (12-60) | V, P, D, A ± C | V, P, MIT, Dex, MTX, VM-26, Ara-C | V, P, MP, MTX | IT MTX | 82 | 29 | 26 | 29 (9) |
| JALSG-ALL 93 (Takeuchi, 2002) | 263 | 31 (15-59) | V, D, P, A, C | MIT, VP-16, Ara-C, MTX, aclarubicin, allo-HCT | MP, MTX | IT MTX, Ara-C, P | 78 | NR | NR | 30 (5) |
| LALA94 (Thomas, 2004) | 922 | 33 (18-79) | V, P, C, (D or I) | MIT + Ara-C or C, Ara-C, MP In addition, high risk disease given allo-HCT or auto-HCT |
MP, MTX, C, Ara-C, V, D, Dex | IT MTX, Ara-C, P ± XRT | 84 | NR | 23 | 37 (3) 30 (5) |
| MD Anderson (Kantarjian, 2004) | 288 | 40 (15-92) | C, V, D, Dex, MTX, Ara-C | C, V, D, Dex, MTX, Ara-C | MP, MTX, V, P | IT MTX | 92 | NR | 32 | NR |
| International trial ALL (Rowe, 2005) | 1521 | (15-59) | V, P, D, A | C, Ara-C, VP-16, MP, MTX, A, V, Dex, D, TG versus allo-HCT versus auto-HCT | V, P, MP, MTX | IT MTX, Ara-C, XRT | 91 | NR | NR Approx 20 mo |
NR OS 38 (5) |
| PETHEMA ALL-93 (Ribera, 2005) | 222 | 27 (15-50) | V, D, P, A, C | V, Dex, MTX, C, Ara-C, A, MP, MIT, T, auto-HCT or allo-HCT | MP, MTX | IT MTX, Ara-C, HC | 82 | NR | 23 | 35 (5) |
| GRAALL-2003 (Huguet, 2009) | 225 | 31 (15-60) | V, P, D, A, C | Ara-C, Dex, A, MTX, V, MP, C, VP-16, P, D, I | V, P, MP, MTX | IT MTX, Ara-C, P, XRT | 94 | NR | NR | 59 (3.5) |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
